Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Mersana Therapeutics Fourth Quarter 2023 Conference Call and Webcast. Currently, all participants are in listen-only mode.
Mersana Therapeutics Inc. (MRSN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 19,364,688 | $44,926,076 | 1.16% | |
| 2. | Balyasny Asset Management Dmitry Balyasny | 9,698,147 | $22,499,701 | +93% | 0.04% |
| 3. | SilverArc Capital Devesh Gandhi | 6,420,136 | $14,894,716 | +29% | 4.43% |
| 4. | Millennium Management Israel Englander | 3,394,440 | $7,875,101 | +56% | 0% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 3,046,782 | $7,068,534 | -11% | 0.17% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.20 | 14,760 | Director | 8,663,673 | 2022-06-02 | Filing | |
| $3.28 | 80,759 | Director | 8,648,913 | 2022-05-31 | Filing | |
| $3.19 | 75,000 | Director | 8,568,154 | 2022-05-26 | Filing | |
| $3.18 | 90,155 | Director | 8,493,154 | 2022-05-25 | Filing | |
| $3.29 | 100,000 | Director | 8,402,999 | 2022-05-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.71 | 29,399 | Director | 125,153 | 2024-01-16 | Filing | |
| $2.71 | 3,357 | Officer | 17,966 | 2024-01-16 | Filing | |
| $2.71 | 5,025 | Officer | 23,328 | 2024-01-16 | Filing | |
| $2.71 | 10,409 | Officer | 199,329 | 2024-01-16 | Filing | |
| $2.71 | 4,381 | Officer | 27,403 | 2024-01-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,328,000 | $26,280,960 | 1.8% | |
| 2. | 8,663,673 | $20,099,721 | 1.92% | |
| 3. | 7,844,282 | $18,198,734 | 0% | |
| 4. | 6,237,588 | $14,471,204 | 0% | |
| 5. | 5,978,327 | $13,869,719 | 2.58% |
News See All
5 Best Rising Penny Stocks To Buy
Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Mersana Therapeutics Third Quarter 2023 Conference Call and Webcast. [Operator Instructions]. Please note, this call is being recorded.
5 Best Biotech Penny Stocks to Buy Now
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) ranks 5th in our list of the best biotech penny stocks to buy now according to hedge funds. Ginkgo Bioworks Holdings, Inc.
15 Best Penny Stocks To Buy Now
Investing in penny stocks is risky but if executed correctly gives investors huge opportunities and exposure to multi-baggers of the future.
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2022 Conference Call and Webcast. Currently, all participants are in a listen-only mode.
5 Best Biotech Stocks Under $10
In this article, we will look at the 5 best biotech stocks under $10.
10 Best Biotech Stocks Under $10
In this article, we will take a look at the 10 best Biotech stocks under $10.
Hedge Fund and Insider Trading News: John Paulson, Ray Dalio, Coatue Management, Blackwells Capital, One Equity Partners, Asia Research & Capital Management, L1 Capital, Mersana Therapeutics Inc (MRSN), and More
Billionaire legendary hedge fund manager Ray Dalio outlined some of the key issues he said investors and non-investors need to pay attention to as the war in Ukraine marks the start of what he described...
Hedge Funds Are Betting On Mersana Therapeutics, Inc. (MRSN)
In this article we will analyze whether Mersana Therapeutics, Inc.
Billionaire Hedge Funds
